当前位置：
X-MOL 学术
›
Mol. Pharmaceutics
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Synergistic Platinum(II) Prodrug Nanoparticles for Enhanced Breast Cancer Therapy.
Molecular Pharmaceutics ( IF 4.5 ) Pub Date : 2020-02-14 , DOI: 10.1021/acs.molpharmaceut.9b01318 Chen-Xi Yang 1 , Lei Xing 1, 2, 3, 4 , Xin Chang 1 , Tian-Jiao Zhou 1 , Yu-Yang Bi 1 , Zhi-Qiang Yu 5 , Zhi-Qi Zhang 6 , Hu-Lin Jiang 1, 2, 3, 4
Molecular Pharmaceutics ( IF 4.5 ) Pub Date : 2020-02-14 , DOI: 10.1021/acs.molpharmaceut.9b01318 Chen-Xi Yang 1 , Lei Xing 1, 2, 3, 4 , Xin Chang 1 , Tian-Jiao Zhou 1 , Yu-Yang Bi 1 , Zhi-Qiang Yu 5 , Zhi-Qi Zhang 6 , Hu-Lin Jiang 1, 2, 3, 4
Affiliation
|
Chemotherapy still accounts for a large proportion of the treatments of tumors, but the drug resistance and side effects caused by long-term chemotherapy should not be underestimated. In this work, the drug combination strategy has been widely developed to overcome the side effects brought by the use of single drugs and improve the therapeutic effect. However, in clinical applications, the co-delivery of drugs is very difficult, and different in vivo kinetics due to different drug properties will lead to a decrease in efficacy. Thus, the design of novel antitumor therapeutic agents, including new platinum agents, represents an area in need of urgent attention. Our investigation implies a promising strategy for the design of a platinum prodrug to enhance the treatment of breast cancer. A dual-drug delivery nanoparticle was developed for enhanced treatment of breast cancer based on a two-into-one co-delivery strategy. Through the synergistic effect of released cisplatin hydrate and tolfenamic acid (COX-2 inhibitor) from the coordination prodrug, the tumor growth is significantly suppressed, and the survival time is greatly extended in breast tumor-bearing mice.
中文翻译：
用于增强乳腺癌治疗的协同铂（II）前药纳米颗粒。
化学疗法仍占肿瘤治疗的很大比例，但是不应低估长期化疗引起的耐药性和副作用。在这项工作中，已经广泛开发了药物组合策略，以克服使用单一药物带来的副作用并提高治疗效果。但是，在临床应用中，药物的共同给药非常困难，并且体内不同由于药物特性不同，药物动力学会导致功效降低。因此，包括新的铂药物在内的新型抗肿瘤治疗剂的设计代表了亟需关注的领域。我们的研究暗示了设计铂前药以增强乳腺癌治疗的有前途的策略。基于二合一共输送策略，开发了一种双药物输送纳米颗粒，用于增强对乳腺癌的治疗。通过从配位前药中释放出顺铂水合物和甲苯磺酸（COX-2抑制剂）的协同作用，显着抑制了肿瘤的生长，并大大延长了荷瘤小鼠的生存时间。
更新日期：2020-02-14
中文翻译：
用于增强乳腺癌治疗的协同铂（II）前药纳米颗粒。
化学疗法仍占肿瘤治疗的很大比例，但是不应低估长期化疗引起的耐药性和副作用。在这项工作中，已经广泛开发了药物组合策略，以克服使用单一药物带来的副作用并提高治疗效果。但是，在临床应用中，药物的共同给药非常困难，并且体内不同由于药物特性不同，药物动力学会导致功效降低。因此，包括新的铂药物在内的新型抗肿瘤治疗剂的设计代表了亟需关注的领域。我们的研究暗示了设计铂前药以增强乳腺癌治疗的有前途的策略。基于二合一共输送策略，开发了一种双药物输送纳米颗粒，用于增强对乳腺癌的治疗。通过从配位前药中释放出顺铂水合物和甲苯磺酸（COX-2抑制剂）的协同作用，显着抑制了肿瘤的生长，并大大延长了荷瘤小鼠的生存时间。
京公网安备 11010802027423号